CSF3 and Sepsis: Therefore, we attempted to summarize the available randomized control trials (RCTs) to determine whether G-CSF or GM-CSF therapy significantly reduced all-cause mortality at 14 days and 28 days, in-hospital mortality and occurrence of adverse events, and increased reversal rate from infection in patients with sepsis.